Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Boston Scientific (NYSE:BSX) in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a $121.00 price objective on the medical equipment provider’s stock.

Other analysts also recently issued reports about the stock. UBS Group lifted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. BTIG Research reissued a “buy” rating and set a $127.00 price objective on shares of Boston Scientific in a report on Tuesday, September 23rd. Finally, Leerink Partners began coverage on Boston Scientific in a research report on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $120.79.

Boston Scientific Stock Performance

Shares of BSX opened at $97.30 on Wednesday. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The stock has a 50-day moving average price of $102.93 and a 200-day moving average price of $102.05.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the firm posted $0.62 earnings per share. Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $17,972,457 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Amplius Wealth Advisors LLC increased its position in Boston Scientific by 5.5% during the 1st quarter. Amplius Wealth Advisors LLC now owns 2,381 shares of the medical equipment provider’s stock valued at $240,000 after purchasing an additional 124 shares during the period. Veracity Capital LLC purchased a new position in Boston Scientific during the 1st quarter valued at $210,000. Leverty Financial Group LLC lifted its position in shares of Boston Scientific by 29.7% in the 1st quarter. Leverty Financial Group LLC now owns 3,977 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 910 shares during the period. Finally, Secure Asset Management LLC bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $418,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.